Effects of switching to everolimus versus continuing a calcineurin inhibitor on biomarkers of fibrosis, tubular injury, inflammation and glomerular injury in renal transplant recipients

Trial Profile

Effects of switching to everolimus versus continuing a calcineurin inhibitor on biomarkers of fibrosis, tubular injury, inflammation and glomerular injury in renal transplant recipients

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 May 2013

At a glance

  • Drugs Everolimus (Primary) ; Calcineurin inhibitors
  • Indications Renal transplant rejection
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 22 May 2013 Results presented at the American Transplant Congress - 13th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
    • 19 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top